A portfolio company of the co-managed sub-fund under the Venture Capital Group, Sailu Medical, has completed its Series A+ financing, accelerating its global layout.

Recently, Shenzhen Sailu Medical Technology Co., Ltd. (hereinafter referred to as "Sailu Medical") announced the completion of its Series A+ financing. This round of financing was led by Fosun Pharma, a leading enterprise in the medical and healthcare industry, followed by Changzhou Weichi Investment, and the existing shareholder Shenzhen Venture Capital continued to increase its investment.

图片1.png

In January 2025, the Salus Pro sequencer independently developed by Sailu Medical obtained the Class III Medical Device Registration Certificate from the National Medical Products Administration (NMPA). It has become the first domestic device in China to achieve full coverage of application scenarios based on the reversible terminator sequencing method, providing a preferred domestic sequencer solution for market demand after Illumina was banned. Adhering to the core concept of "independent technology + industrial closed loop", the company has established a full-chain R&D system covering optics, fluidics, chips, reagents and other fields, built an all-domestic sequencing + super-resolution spatial omics platform, accumulated over 100 authorized patents, and its products cover scientific research, clinical and agricultural fields. It is committed to becoming a global leader in life science tools.

This round of financing is another important milestone for Sailu Medical following its Series A financing and the certification of Salus Pro. Further cooperation with leading industrial investors in the medical industry will continuously enhance Sailu Medical's product R&D capabilities and global commercialization capabilities.

In December 2023, Nanjing Borui Jiatai Phase II Equity Investment Partnership (Limited Partnership) participated in Sailu Medical's Series A financing. Established in February 2021, this fund is managed by Borui Yuye (Shanghai) Equity Investment Management Co., Ltd., with a total scale of 1.5 billion yuan. Among them, the industrial fund managed by Nanjing Innovation Investment Group contributed 100 million yuan, accounting for 6.67%. The fund mainly invests in high-quality medical and health industry enterprises with growth potential, covering pharmaceuticals, biotechnology, medical services, medical devices, equipment, diagnostics, animal health and other medical and health-related fields.

Source: Zhou Xin from the Fund Department Review: Xue Yao Release: You Yi